Yangli Zhou

发表

Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).

Sheng-yong Yang, Shulei Pan, Yangli Zhou, 2020, European journal of medicinal chemistry.

DHODH and cancer: promising prospects to be explored

Na Sang, Lei Tao, Yinglan Zhao, 2021, Cancer & metabolism.

Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1

Lin Cheng, Jun Zou, Yifei Wang, 2022, Nature Chemical Biology.

ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.

Sheng-yong Yang, Hu Zhang, X. Cen, 2019, Cancer letters.

Discovery of selective BPTF bromodomain inhibitors by screening and structure-based optimization.

Sheng-yong Yang, Yinping Guo, Yangli Zhou, 2021, Biochemical and biophysical research communications.

Discovery of Small Molecule Agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R)

Yifei Wang, Xin Yang, Yangli Zhou, 2022, J. Chem. Inf. Model..

Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.

Lei Tao, Yinglan Zhao, Youfu Luo, 2022, European journal of medicinal chemistry.

The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy

Na Sang, Sheng-yong Yang, Yinglan Zhao, 2021, Medical Oncology.

Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.

Sheng-yong Yang, Yinglan Zhao, Yangli Zhou, 2016, Bioorganic & medicinal chemistry letters.

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model

Yuquan Wei, Yiguo Hu, Sheng-yong Yang, 2021 .

5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors

Sheng-Yong Yang, Yangli Zhou, Ying-Lan Zhao, 2015, Molecules.

Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation.

Yangli Zhou, Zhenyu Yang, Lei Zhong, 2020, Bioorganic & medicinal chemistry letters.

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

Yuquan Wei, Yiguo Hu, Sheng-yong Yang, 2021, Science.

Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.

X. Cen, Yinglan Zhao, Yangli Zhou, 2023, European journal of medicinal chemistry.

Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain.

Yifei Wang, Mingli Xiang, Xin Yang, 2023, Journal of medicinal chemistry.

Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer

Sheng-yong Yang, X. Cen, Yinglan Zhao, 2020, Therapeutic advances in medical oncology.

Corrigendum to "ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway" [Cancer Lett. 454 (2019) 179-190].

Sheng-yong Yang, X. Cen, Lei Tao, 2019, Cancer letters.

Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation

Yangli Zhou, Miao-Miao Niu, Hai Zhang, 2022, Frontiers in Pharmacology.

Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B

Zhiqian Chen, Na Sang, X. Cen, 2023, MedComm.

Synthesis and biological evaluation of novel pyrazole amides as potent mitochondrial complex I inhibitors.

X. Cen, Yinglan Zhao, Youfu Luo, 2023, European journal of medicinal chemistry.

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51

Junhong Han, Na Sang, Yong Peng, 2023, Nature communications.